Related Experiment Videos
Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata
Sriram Rajagopal1, R Ajaya Kumar, Dhanvanthri S Deevi
1Discovery Research, Dr. Reddy's Laboratories, Miyapur, Hyderabad, India-500050. sriramrajagopal@drreddys.com
Journal of Experimental Therapeutics & Oncology
|December 4, 2003
Summary
Andrographolide, derived from the Andrographis paniculata plant, demonstrates potent anticancer effects by halting cancer cell division and boosting immune responses. This compound shows promise as a novel therapeutic agent for cancer treatment.
Area of Science:
- Pharmacology
- Immunology
- Oncology
Background:
- Andrographis paniculata extract exhibits diverse pharmacological effects.
- Andrographolide is the primary active compound responsible for these activities.
Purpose of the Study:
- To investigate the cellular mechanisms and targets of andrographolide in human cancer and immune cells.
- To evaluate the direct and indirect anticancer potential of andrographolide.
Main Methods:
- In vitro studies on human cancer cell lines and immune cells (lymphocytes).
- In vivo studies using B16F0 melanoma and HT-29 xenograft models.
- Analysis of cell-cycle regulation, cytokine production, and immune cell markers.
Main Results:
- Andrographolide inhibited cancer cell proliferation by inducing G0/G1 cell-cycle arrest via p27 induction and CDK4 downregulation.
- The compound stimulated lymphocytes, increasing interleukin-2 and tumor necrosis factor-alpha production.
- Enhanced lymphocyte cytotoxic activity against cancer cells and demonstrated in vivo anticancer efficacy.
Conclusions:
- Andrographolide possesses both direct anticancer and immunomodulatory properties.
- It effectively targets cancer cells and enhances anti-tumor immune responses.
- Andrographolide represents a promising pharmacophore for developing new cancer therapeutics.